Literature DB >> 1310154

Inhibitory effect of myristylation on transrepression by FBR (Gag-Fos) protein.

N Kamata1, J T Holt.   

Abstract

The myristylated v-fos product, FBR murine sarcoma virus (Gag-Fos) protein, exhibits a lower level of transrepression of the serum response element (SRE) than does c-fos protein (Fos). Mutation of the N-terminal myristylation site in FBR protein restored SRE transrepression. Replacement of N-terminal viral Gag sequences with the Fos N terminus also restored this activity, providing additional evidence that myristylation inhibits transrepression by FBR protein. However, the myristylated Gag domain did not inhibit SRE transrepression when fused to Fos, indicating that myristylation of a fos protein is not by itself sufficient to prevent SRE transrepression and that C-terminal mutation is necessary to inhibit transrepression by N myristylation. Comparison of transfection results with Fos C-terminal deletion mutants and the Fos/FBR chimeric mutant revealed that the FBR C terminus retained the potential for transrepression despite deletion of the normal Fos C terminus, whereas similar Fos deletion mutants did not. These results indicate that both N- and C-terminal mutations are required to inhibit transrepression by FBR protein and that multiple structural mutations accompanied by posttranslational protein modification alter gene regulation by FBR protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310154      PMCID: PMC364321          DOI: 10.1128/mcb.12.2.876-882.1992

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  61 in total

Review 1.  Oncogenic conversion by regulatory changes in transcription factors.

Authors:  B Lewin
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Redox regulation of fos and jun DNA-binding activity in vitro.

Authors:  C Abate; L Patel; F J Rauscher; T Curran
Journal:  Science       Date:  1990-09-07       Impact factor: 47.728

3.  The inner core of the serum response element mediates both the rapid induction and subsequent repression of c-fos transcription following serum stimulation.

Authors:  V M Rivera; M Sheng; M E Greenberg
Journal:  Genes Dev       Date:  1990-02       Impact factor: 11.361

4.  Transcriptional activation and repression by Fos are independent functions: the C terminus represses immediate-early gene expression via CArG elements.

Authors:  D Gius; X M Cao; F J Rauscher; D R Cohen; T Curran; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

5.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

6.  Phosphorylation of the C terminus of Fos protein is required for transcriptional transrepression of the c-fos promoter.

Authors:  R Ofir; V J Dwarki; D Rashid; I M Verma
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

7.  Myristylation alters DNA-binding activity and transactivation of FBR (gag-fos) protein.

Authors:  N Kamata; R M Jotte; J T Holt
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

8.  Myristic acid is attached to the transforming protein of Rous sarcoma virus during or immediately after synthesis and is present in both soluble and membrane-bound forms of the protein.

Authors:  J E Buss; M P Kamps; B M Sefton
Journal:  Mol Cell Biol       Date:  1984-12       Impact factor: 4.272

9.  Antisense mapping of the c-fos promoter: role of the serum response element.

Authors:  C Robinson-Benion; N Kamata; J T Holt
Journal:  Antisense Res Dev       Date:  1991

10.  Viral and cellular fos proteins: a comparative analysis.

Authors:  T Curran; A D Miller; L Zokas; I M Verma
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

View more
  1 in total

1.  Myristylation of FBR v-fos dictates the differentiation pathways in malignant osteosarcoma.

Authors:  R M Jotte; J T Holt
Journal:  J Cell Biol       Date:  1996-10       Impact factor: 10.539

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.